Loading institutional data...
Loading institutional data...
Held by 316 of 5,944 reporting institutions (95th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $76.97 today, the market must believe free cash flow compounds 25.9%/yr for a decade (off $130M normalized FCF).
2-stage DCF · 0.13B shares · net debt $0
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $642.8M 100.0% | $610.8M 100.0% | $618.7M 100.0% | $516.4M 100.0% | $490.5M 100.0% | $298.8M 100.0% | $245.9M 100.0% | $146.3M 100.0% | $71.1M 100.0% |
| Cost of Revenue | $198.9M 30.9% | $196.3M 32.1% | $209.4M 33.8% | $120.4M 23.3% | $74.1M 15.1% | $58.5M 19.6% | $61.0M 24.8% | $28.7M 19.6% | $10.6M 14.9% |
| Gross Profit | $443.9M 69.1% | $414.5M 67.9% | $409.3M 66.2% | $396.0M 76.7% | $416.4M 84.9% | $240.4M 80.4% | $184.9M 75.2% | $117.7M 80.4% | $60.5M 85.1% |
| Selling, General & Admin | $316.1M 49.2% | $344.3M 56.4% | $343.3M 55.5% | $298.3M 57.8% | $257.6M 52.5% | $202.3M 67.7% | $130.8M 53.2% | $87.9M 60.1% | $46.7M 65.7% |
| Total Operating Expenses | $504.9M 78.5% | $609.0M 99.7% | $674.6M 109.0% | $564.0M 109.2% | $468.7M 95.5% | $774.5M 259.2% | $215.4M 87.6% | $228.4M 156.1% | $78.9M 111.0% |
| Operating Income | -$61.0M -9.5% | -$194.6M -31.9% | -$265.3M -42.9% | -$167.9M -32.5% | -$52.3M -10.7% | -$534.1M -178.7% | -$30.6M -12.4% | -$110.8M -75.7% | -$18.4M -25.8% |
| Interest Expense | $0 0.0% | $4K 0.0% | $33K 0.0% | $476K 0.1% | $866K 0.2% | $1.7M 0.6% | $3.1M 1.3% | $2.4M 1.6% | $811K 1.1% |
| Interest & Investment Income | $20.0M 3.1% | $18.9M 3.1% | $16.9M 2.7% | $6.6M 1.3% | $206K 0.0% | $1.5M 0.5% | $2.8M 1.1% | $1.0M 0.7% | $308K 0.4% |
| Other Income (Expense), net | $21.1M 3.3% | $16.9M 2.8% | $16.6M 2.7% | $6.0M 1.2% | -$1.5M -0.3% | -$334K -0.1% | -$460K -0.2% | -$1.6M -1.1% | -$366K -0.5% |
| Pretax Income | -$39.9M -6.2% | -$177.7M -29.1% | -$248.8M -40.2% | -$162.0M -31.4% | -$53.7M -11.0% | -$534.5M -178.8% | -$31.0M -12.6% | -$112.4M -76.8% | -$18.7M -26.4% |
| Income Tax Expense | $3.6M 0.6% | $4.9M 0.8% | $6.3M 1.0% | $4.0M 0.8% | $4.5M 0.9% | $8.3M 2.8% | $218K 0.1% | $87K 0.1% | $21K 0.0% |
| Net Income | -$43.5M -6.8% | -$182.6M -29.9% | -$255.1M -41.2% | -$166.0M -32.1% | -$58.2M -11.9% | -$542.7M -181.6% | -$31.3M -12.7% | -$112.5M -76.9% | -$18.8M -26.4% |
| Per Share | |||||||||
| EPS (Basic) | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 | $-0.80 | — | — |
| EPS (Diluted) | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 | $-0.80 | — | — |
| Weighted Avg Shares (Basic) | 124.7M | 120.5M | 117.2M | 113.9M | 110.3M | 101.2M | 39.1M | — | — |
| Weighted Avg Shares (Diluted) | 124.7M | 120.5M | 117.2M | 113.9M | 110.3M | 101.2M | 39.1M | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $130M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 9 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -5%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 9 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Interest last disclosed in FY2024 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
Nothing notable to watch.
Where each multiple sits in its own 7-yr range · 57th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 7-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 19.6 | 24.8 | 19.6 | 15.1 | 23.3 | 33.8 | 32.1 | 30.9 |
| Gross Profit | 80.4 | 75.2 | 80.4 | 84.9 | 76.7 | 66.2 | 67.9 | 69.1 |
| SG&A | 60.1 | 53.2 | 67.7 | 52.5 | 57.8 | 55.5 | 56.4 | 49.2 |
| Operating Income | -75.7 | -12.4 | -178.7 | -10.7 | -32.5 | -42.9 | -31.9 | -9.5 |
| Income Tax | 0.1 | 0.1 | 2.8 | 0.9 | 0.8 | 1.0 | 0.8 | 0.6 |
| Net Income | -76.9 | -12.7 | -181.6 | -11.9 | -32.1 | -41.2 | -29.9 | -6.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on TXG: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| TXG | $9.8B | — | — | 15.3× | 5.2% | 69.1% | -6.8% | -5.5% | -5.5% | — | 316 |
Peers = companies sharing TXG's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.